As of September 7, 2016, there have been 685 (683 MS, 3 CD) confirmed PML cases worldwide.
As of August 31, 2016, overall PML incidence: 4.22 per 1000 patients (95% CI 3.91 to 4.55 per 1000 patients). 23% of patients have died; 77% of patients are alive with varying levels of disability.
As of June 30, 2016, approximately 156,500 patients received natalizumab in post-marketing setting worldwide.
After the re-approval of Tysabri® (Natalizumab), there were the expected/feared PML disorders. I have generated a table with the main available data from June 2008 to june 2016.
I would be grateful for additional information via comment or e-mail. Tysabri®, Avonex®, Rebif® & Copaxone® are trademarks.